# WinnTi Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/winnti-medical

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: www.winnti.com
- Total disclosed funding: $47M
- Latest round: Series B (Aug 24, 2017)
- Investors on record: 8

## About

WinnTi Medical develops innovative orthopedic solutions, focusing on advanced surgical instruments and rehabilitation technologies to enhance patient recovery and improve outcomes in orthopedic care.WinnTi Medical, founded in 2013, is based in Shanghai, China, and specializes in orthopedic solutions for trauma and spinal diseases. The company's CEO is Edson Selaolo. In August 2017, WinnTi Medical raised CNY 210.000 mn in a Series B funding round led by HighLight Capital, with participation from IDG Capital, bringing their total amount raised to CNY 210.000 mn. They have engaged in 3 deals since inception, with the most recent one occurring on August 24, 2017.WinnTi Medical specializes in professional orthopedic solutions, primarily focusing on the treatment of limb, pelvic trauma, and spinal diseases. Their product lineup includes advanced orthopedic surgical instruments and rehabilitation technologies that enhance patient recovery. These products are utilized by healthcare professionals, including orthopedic surgeons and rehabilitation specialists, in hospitals and clinics. Their market presence extends internationally, including key regions such as North America and Europe.WinnTi Medical's revenue model is based on direct sales to healthcare institutions, including hospitals and clinics, for surgical instruments and rehabilitation equipment. Business transactions are often structured through contracts, ensuring tailored solutions for clients. The company also partners with medical distributors and wholesalers to expand its reach within the healthcare ecosystem, deriving its revenue primarily from these direct sales and partnerships.WinnTi Medical plans to leverage recent funding from its Series B round to support the introduction of new orthopedic products designed to enhance surgical efficiency and patient care. The company is also targeting expansion into new geographic markets, focusing on regions like Europe and North America by the end of 2023. The funding raised in August 2017 will be instrumental in funding these initiatives and broader market penetration.

## Funding rounds

- Series B, Aug 24, 2017 — IDG Capital, PreIPO Capital Partners, HighLight Capital, KPC Pharmaceuticals, Yingtao Investment, Huiyuan Investment
- Series B, Mar 27, 2015, $34M — IDG Capital, HighLight Capital
- Series A, Sep 18, 2014, $13M — IDG Capital, LYFE Capital, CreditEase Wealth Management

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A, Series B
- LYFE Capital — Series A
- CreditEase Wealth Management (https://capitalatlas.ai/funds/creditease-wealth-management) — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- PreIPO Capital Partners (https://capitalatlas.ai/funds/preipo-capital-partners) — Series B
- KPC Pharmaceuticals — Series B
- Yingtao Investment — Series B
- Huiyuan Investment — Series B